Special Issue "Aldose Reductase: Its Function, Structure and Role in Human Diseases"
Deadline for manuscript submissions: 27 March 2024 | Viewed by 306
Interests: oxidative stress-induced signal transduction mechanisms; pathophysiology of secondary diabetic complications; carcinogenesis; inflammatory complications; therapeutic development of small molecular inhibitors and anti-oxidants
This special issue is dedicated to articles related to aldose reductase and its function, structure, and role in various human diseases. Aldose reductase is the first and rate-limiting enzyme that catalyzes the conversion of glucose to sorbitol in the polyol pathway of glucose metabolism. In the past few decades, several studies have shown that aldose reductase causes several secondary diabetic complications, such as diabetic retinopathy, neuropathy, nephropathy, cardiomyopathy, and cataractogenesis via promoting cellular osmotic stress and oxidative stress. Various aldose reductase inhibitors have been developed from natural and synthetic sources and evaluated in several preclinical and clinical studies on diabetic complications. Most of these inhibitors failed in clinical studies for treating secondary diabetic complications. However, only one aldose reductase inhibitor is currently on the market to control diabetic neuropathy in some Asian countries. Further, recent studies have also shown that aldose reductase inhibitors, besides preventing secondary diabetic complications, could also prevent various inflammatory complications such as asthma, sepsis, uveitis, and colon and breast cancers. These studies have indicated the potential therapeutic development of aldose reductase inhibitors for the treatment of inflammatory complications and cancer. However, additional preclinical and clinical studies are required to understand the molecular mechanisms through which the aldose reductase mediates these human diseases. The development of potent inhibitors with high specificity and low adverse effects is necessary for efficient therapeutic implementation. This special issue invites novel structural and computational studies, functional studies, preclinical and clinical research studies, and comprehensive reviews on aldose reductase.
Dr. Kota V. Ramana
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- aldose reductase
- aldose reductase inhibitors
- molecular modeling